Wesley on Nostr: Within the next 6 months to a year we’ll likely hear of a new “blockbuster” ...
Within the next 6 months to a year we’ll likely hear of a new “blockbuster” drug for diabetes and obesity. So much mainstream acknowledgment of risk of GLP-1 like Ozempic. Liraglutide (Victoza) patent ending end of 2023.
Published at
2023-10-06 17:08:46Event JSON
{
"id": "605a6cee261fc9d11ac760dc5a38b8e09725ebf98bb073978b097a427d9b2ec5",
"pubkey": "2ea03c1b34d1192ae3a2709b686e1140c35bb48c35c3c28539ff38367104bf20",
"created_at": 1696612126,
"kind": 1,
"tags": [],
"content": "Within the next 6 months to a year we’ll likely hear of a new “blockbuster” drug for diabetes and obesity. So much mainstream acknowledgment of risk of GLP-1 like Ozempic. Liraglutide (Victoza) patent ending end of 2023.",
"sig": "5e27a73261a5f8f89daa189543933a60cddb381a576a45c5514403656af2a6225dc37e9489f0d8d43e591a0c4aaad3d4f73e90769c8bf8039868bba060c4167c"
}
